{"url_path":"/sec/dyn/8-k/2026-06-03/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-03","source_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001193125-26-254597-index.html","accession_number":"0001193125-26-254597","cik":"0001818794","ticker":"DYN","issuer_name":"Dyne Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1818794/0001193125-26-254597-index.html","primary_entity_key":"0001818794","primary_entity_name":"Dyne Therapeutics, Inc."},"word_count":144,"has_tables":true,"body_markdown":"Item 7.01 Regulation FD Disclosure.\n\n \n\nOn June 3, 2026, Dyne Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the registrational expansion cohort (the “REC”) of its Phase 1/2 ACHIEVE trial of zeleciment basivarsen (“z-basivarsen,” also known as DYNE-101) in individuals with myotonic dystrophy type 1 (“DM1”). A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.\n\nThe information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing."}